Abstract
Following myocardial infarction (MI), a dynamic and complex process called wound healing is initiated, aiming to produce a robust scar and limit adverse remodeling of the left ventricle (LV). Cardiac fibroblasts (CFs) - the most populous cardiac cell-type - differentiate into myofibroblasts under the influence of post-MI mechanical stress, transforming growth factor β (TGF-β) and various inflammatory signals. Myofibroblasts are contractile cells that start producing extracellular matrix (ECM) components and secrete factors that orchestrate wound healing, but also promote adverse cardiac remodeling that can progress to life-threatening heart failure (HF). Due to their vital role in the wound healing and LV remodeling after MI, (myo)fibroblasts have been receiving more and more attention lately as targets for anti-HF treatment strategies. In this review, we will summarize the current knowledge regarding the cardiac (myo)fibroblast characteristics, discuss the signaling pathways and the factors that affect their migration, proliferation and differentiation post-MI, as well as their ECM-depositing capabilities. Finally, we will provide an overview of the latest innovative research that is targeting the (myo)fibroblast, in an attempt to limit adverse remodeling and prevent HF.
Keywords: Fibroblast, myofibroblast, myocardial infarction, heart, cardiac remodeling, heart failure.
Current Pharmaceutical Design
Title:Cardiac (myo)fibroblast: Novel Strategies for its Targeting Following Myocardial Infarction
Volume: 20 Issue: 12
Author(s): Evangelos P. Daskalopoulos, Kevin C.M. Hermans and W. Matthijs Blankesteijn
Affiliation:
Keywords: Fibroblast, myofibroblast, myocardial infarction, heart, cardiac remodeling, heart failure.
Abstract: Following myocardial infarction (MI), a dynamic and complex process called wound healing is initiated, aiming to produce a robust scar and limit adverse remodeling of the left ventricle (LV). Cardiac fibroblasts (CFs) - the most populous cardiac cell-type - differentiate into myofibroblasts under the influence of post-MI mechanical stress, transforming growth factor β (TGF-β) and various inflammatory signals. Myofibroblasts are contractile cells that start producing extracellular matrix (ECM) components and secrete factors that orchestrate wound healing, but also promote adverse cardiac remodeling that can progress to life-threatening heart failure (HF). Due to their vital role in the wound healing and LV remodeling after MI, (myo)fibroblasts have been receiving more and more attention lately as targets for anti-HF treatment strategies. In this review, we will summarize the current knowledge regarding the cardiac (myo)fibroblast characteristics, discuss the signaling pathways and the factors that affect their migration, proliferation and differentiation post-MI, as well as their ECM-depositing capabilities. Finally, we will provide an overview of the latest innovative research that is targeting the (myo)fibroblast, in an attempt to limit adverse remodeling and prevent HF.
Export Options
About this article
Cite this article as:
Daskalopoulos P. Evangelos, Hermans C.M. Kevin and Blankesteijn Matthijs W., Cardiac (myo)fibroblast: Novel Strategies for its Targeting Following Myocardial Infarction, Current Pharmaceutical Design 2014; 20 (12) . https://dx.doi.org/10.2174/13816128113199990452
DOI https://dx.doi.org/10.2174/13816128113199990452 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Role of Galectins in Allergic Disorders
Recent Patents on Inflammation & Allergy Drug Discovery New Developments In Treatment After Lung Transplantation
Current Pharmaceutical Design Vasopressin Antagonists as Anxiolytics and Antidepressants: Recent Developments
Recent Patents on CNS Drug Discovery (Discontinued) Hematopoietic Progenitor and Stem Cells Circulate by Surfing on Intracellular Ca2+ Waves: A Novel Target for Cell-based Therapy and Anti-cancer Treatment?
Current Signal Transduction Therapy Relaxin in Vascular Physiology and Pathophysiology: Possible Implications in Ischemic Brain Disease
Current Neurovascular Research Targeting Ion Channels in Leukemias: A New Challenge for Treatment
Current Medicinal Chemistry Histone Deacetylase (HDAC) Inhibitors - emerging roles in neuronal memory, learning, synaptic plasticity and neural regeneration
Current Neuropharmacology Alzheimers Disease, Ceramide, Visfatin and NAD
CNS & Neurological Disorders - Drug Targets Novel Biomarkers for Risk Stratification and Identification of Lifethreatening Cardiovascular Disease: Troponin and Beyond
Current Cardiology Reviews Targeting NO/cGMP Signaling in the CNS for Neurodegeneration and Alzheimer’s Disease
Current Medicinal Chemistry Anesthetic Considerations for Electroconvulsive Therapy-Especially Hemodynamic and Respiratory Management
Current Psychiatry Reviews Role of microRNAs in Vascular Remodeling
Current Molecular Medicine Antimicrobial Drug Interactions in the Critically Ill Patients
Current Clinical Pharmacology Cardiovascular Effects of Liraglutide
Current Hypertension Reviews The Role of Mesenchymal Stem Cells in Immune Response
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Antioxidant and Antiradical Activities Assessment in Two Hawthorn Species Fruit Components
Current Nutrition & Food Science The Prostaglandin Agonist Beraprost Aggravates Doxorubicin-mediated Apoptosis by Increasing iNOS Expression in Cardiomyocytes
Current Vascular Pharmacology Resistance to Diuretics in Heart Failure: Any Role for Empagliflozin?
Current Vascular Pharmacology Biomarkers in Molecularly Targeted Therapy for Cancer
Recent Patents on Biomarkers Role of Mitochondrial Translocator Protein (18 kDa) on Mitochondrial- Related Cell Death Processes
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery